Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

Adding polatuzumab vedotin (Polivy) to standard-of-care treatment significantly improved overall survival (OS) in patients ...

Polivy is a type of targeted therapy called an antibody-drug conjugate. This antibody-drug conjugate is made up of an antibody that is attached to an anti-cancer medicine. Polivy is used to treat ...

Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of non-Hodgkin’s ...

As with other drugs, Polivy (polatuzumab vedotin-piiq) can cause side effects, such as nausea, fatigue, and diarrhea. If side effects of Polivy become difficult to tolerate, talk with your doctor ...

Polivy (polatuzumab vedotin-piiq) is a prescription biologic drug that treats certain types of B-cell lymphoma. Polivy can cause side effects that range from mild to serious. Examples include ...

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...